fool.comAUG 231 min read$CAH

What to Know About the Latest Sale From Cardinal Health's Chief Accounting Officer

Cardinal Health's Chief Accounting Officer, Mary C. Scherer, sold 2,302 shares on August 19 at a weighted-average price of $237.39, according to an SEC filing. She now owns 2,811 shares, representing 0.001% of the company. Cardinal Health reported $254.2 billion in revenue and $1.7 billion in net income for the trailing 12 months. The company operates in healthcare services and products, serving hospitals, pharmacies, and clinical laboratories.

Original reporting

fool.com

Published Aug 23, 2026, 2:45 PM UTC

Analysis

alphai AI DeskAI-generated

Added to alphai Aug 23, 2026, 3:19 PM UTC. Informational, not investment advice.

How this was made

alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About alphai AI Desk Scoring methodology Report an issue

What to Know About the Latest Sale From Cardinal Health's Chief Accounting Officer — source image — Source · fool.com

Decision brief

The 30-second read

$CAHNeutralLow

Why it matters

The insider sale is routine and does not alter the company's fundamentals.

Market read

Routine insider transaction with negligible market impact.

What to watch

The sale coincides with a stable revenue base; no operational changes indicated.

Relevance 4/10Novelty 4/10Timing: August 19 filing disclosed on August 23

Background

Cardinal Health is a large healthcare services provider with $254.2B TTM revenue and $55B market cap.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$CAHNeutralHigh confidence

Context

Form 4 filing shows CAO sold 2,302 shares (~$546k) at $237.39, retaining a 0.001% stake.

Expected impact

No material impact on stock price.

Evidence & confidence

The sale size is small relative to market cap and insider stake, so market reaction is expected to be negligible.

Market effects

Sector

None; typical insider sale in healthcare distribution sector.

Regional

No regional effect.

Global

Minimal.

Counterpoint

What could challenge this read

If investors view insider sales as a negative signal, they may short CAH, but the amount is trivial.

Key entities

Company
Cardinal Health, Inc.
Global healthcare services and products provider.
Executive
Mary C. Scherer
Chief Accounting Officer of Cardinal Health.

Read at source ← All news

SEP 7

$CAHMedAI 8/10

4 companies on verge of settling US opioid lawsuits

AmerisourceBergen, Cardinal Health, McKesson, and Johnson & Johnson are nearing a $26B settlement for opioid lawsuits. New York reached a separate $1B deal with the distributors. Johnson & Johnson will contribute up to $5B nationally. Trials continue elsewhere.

pressdemocrat.com3 min

SEP 3

$CAHHighAI 8/10

Jim Cramer Notes Cardinal Health (CAH) is “Too Attractive to Ignore”

Jim Cramer highlighted Cardinal Health (CAH) as a favorite, citing its specialty pharmaceuticals and healthcare services growth. Q4 revenue rose 6% to $63.7B but missed estimates, while adjusted EPS was $2.91. Fiscal 2027 guidance includes non-GAAP EPS of $12.40-$12.60 and adjusted free cash flow of $3.5B-$4B. Risks include execution, drug pricing, and customer concentration.

insidermonkey.com3 min

AUG 19

$CAHHighAI 8/10

Cardinal Health’s (CAH) Big Earnings Beat Hides a More Complicated Story

Cardinal Health (CAH) reported Q4 2026 earnings with non-GAAP EPS up 40% YoY to $2.91, including a $0.31 one-time tariff refund. Revenue reached $63.7B, up 6% YoY. Full-year adjusted free cash flow hit $5B. Guidance suggests slower growth ahead. The company expanded its buyback program by $5B to $6.4B.

yahoo.com2 min

AUG 18

$CAHHighAI 9/10

Cardinal Health (CAH) Q4 2026 Earnings Call Transcript

Cardinal Health (CAH) reported Q4 2026 revenue of $63.7B, up 6%, driven by Pharmaceutical and Specialty Solutions. Non-GAAP EPS was $2.91, up 40%. Fiscal 2027 guidance includes 3-5% pharma revenue growth and 8-11% profit growth. The company plans $1B in share repurchases and increased its authorization to $6.4B. Management cited risks from geopolitical instability and IRA price changes.

fool.com6 min

AUG 18

$CAHMed

5 Revealing Analyst Questions From Cardinal Health’s Q2 Earnings Call

Cardinal Health reported Q2 revenue of $63.67B, below Wall Street’s $65.42B estimate, but adjusted EPS of $2.60 beat the $2.42 estimate. Management cited demand in Pharmaceutical and Specialty Solutions and progress on its improvement plan in Global Medical Products and Distribution. Guidance for FY2027 adjusted EPS midpoint was $12.50. Analysts asked about specialty growth, M&A, regulatory impacts, and input costs.

financialcontent.com7 min

AUG 17

$BAXMed

Baxter’s interim CFO is leaving for Cardinal Health

Baxter said in SEC filings that interim CFO Anita Zielinski will leave in September. She will join Cardinal Health as chief accounting officer and SVP of finance on Nov. 5, with a $750,000 sign-on bonus and $1 million in time-vesting RSUs. Baxter has not named a successor. Baxter recently raised its full-year outlook to 3%-4% sales growth and adjusted EPS of $1.95-$2.15.

massdevice.com4 min